Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Human Study of ChAdOx1-HBV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04297917
Recruitment Status : Recruiting
First Posted : March 6, 2020
Last Update Posted : August 19, 2021
Sponsor:
Information provided by (Responsible Party):
Vaccitech (UK) Limited

Brief Summary:
This is a Phase 1, first in human study of ChAdOx1-HBV. The study will be conducted in 40 healthy participants and 12 participants with CHB and virally suppressed with oral antiviral medication. This will be an open-label, non randomised dose escalation study comparing the safety, tolerability and immunogenicity of 2 different doses of ChAdOx1 HBV vaccine. T cell responses in healthy participants who have received a prior two-dose series of either AZD1222 or the Pfizer mRNA COVID 19 vaccine will be compared.

Condition or disease Intervention/treatment Phase
Hepatitis B Healthy Biological: ChAdOx1-HBV Phase 1

Detailed Description:

This is a first in man human study of a therapeutic vaccine for chronic hepatitis B infection(ChAdOx1-1HBV). The vaccine will be given to participants in a dose escalation strategy (two doses). Five healthy participants will be administered the low dose first (cohort 1). Dose escalation will only be initiated in the next 5 healthy participants (cohort 2) following Safety Monitoring Committee (SMC) review.

Six CHB participants will be administered the low dose (cohort 3) before the dose escalation is initiated in the remaining 6 CHB participants (cohort 4).

Thirty healthy participants (15 who have received two doses of AZD1222 [cohort 5] and 15 who have received two doses of Pfizer mRNA COVID 19 vaccine [cohort 6]) will be dosed in parallel with the high dose used in cohorts 2 and 4.

Each participant will receive 1 dose of the vaccine (intramuscular injection). Participants (Volunteers & patients) in cohorts 1 to 4 will attend up to 9 study visits and cohorts 5 & 6 will attend up to 4 visits in total. The last visit will be 24 weeks after vaccination for cohorts 1 to 4 and 12 weeks for cohorts 5 & 6.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The participants will be recruited in 6 cohorts as follows - Cohort 1 - Healthy Volunteers - Low dose Vaccine - 5 participants Cohort 2 - Healthy Volunteers - High dose Vaccine - 5 participants Cohort 3 - Participants with Chronic Hepatitis B infection - Low dose - 6 participants Cohort 4 - Participants with Chronic Hepatitis B infection - High dose - 6 participants Cohort 5 - Healthy Volunteers who have completed 2 doses of COVID-19 AZD1222 vaccine Cohort 6 - Healthy Volunteers who have completed 2 doses of Pfizer mRNA COVID 19 vaccine
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Monotherapy Study to Evaluate the Safety, Tolerability & Immunogenicity of Vaccination With Candidate Chimpanzee Adenovirus-vectored HepB Virus Vaccine ChAdOx1 HBV in Healthy Participants & Participants With Chronic HepB Infection
Actual Study Start Date : February 10, 2019
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Healthy Volunteers with low dose vaccination
5 Healthy Volunteers receiving low dose vaccination
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine

Experimental: Healthy Volunteers with high dose vaccination
5 Healthy Volunteers receiving high dose vaccination
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine

Experimental: Chronic Hepatitis B participants with low dose vaccination
6 participants with Chronic Hepatitis B infection receiving low dose vaccination
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine

Experimental: Chronic Hepatitis B participants with high dose vaccination
6 participants with Chronic Hepatitis B infection receiving high dose vaccination
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine

Experimental: Healthy Volunteers who have had COVID-19 AZD1222 vaccine
15 participants who have had 2 doses of COVID-19 AZD1222 vaccine
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine

Experimental: Healthy Volunteers who have had Pfizer mRNA COVID 19 vaccine
15 participants who have had Pfizer mRNA COVID 19 vaccine
Biological: ChAdOx1-HBV
chimpanzee adenovirus-vectored hepatitis B virus vaccine




Primary Outcome Measures :
  1. Adverse events [ Time Frame: From screening up to day 7 for solicited AE's, unsolicited events through study completion (on average 6 months) ]
    Adverse events and/or adverse events leading to study discontinuation

  2. Serious adverse events [ Time Frame: from day 0 to up to 6 months ]
    Serious adverse events related to the study vaccine

  3. Grade ≥3 local and systemic reactions [ Time Frame: from day 0 to day 3 ]
    Local reactogenicity - pain, induration, warmth, erythema at the vaccination site Systemic: feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, malaise



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adult males or females aged ≥18 to ≤65 years at screening
  2. Body Mass Index ≤30 kg/m2
  3. Able to provide informed consent indicating they understand the purpose of, and procedures required, for the study and are willing to participate
  4. If female, willing not to become pregnant up to 8 weeks after last dose of study vaccine, not breast feeding
  5. If female: Not pregnant, and one of the following:

    • Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are post menopausal, as defined by no menses in ≥1 year)
    • Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant
    • Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to study vaccine and 8 weeks after study vaccine. Highly effective methods of contraception include one or more of the following:

    Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant, Hormonal (oral, intravaginal, transdermal, implantable or injectable), An intrauterine hormone releasing system, An intrauterine device and Bilateral tubal occlusion

    Healthy participants (cohorts 1 and 2):

  6. Considered to be healthy with no current conditions that may significantly impair participant safety or influence study results, in the opinion of the Investigator

    Participants with well controlled CHB (cohorts 3 and 4):

  7. Documented evidence of chronic HBV infection (e.g. HBsAg positive ≥6 months with detectable HBsAg levels at screening)
  8. Receipt of only either entecavir or tenofovir for at least 12 months before screening
  9. Virally suppressed (HBV DNA <40 IU/mL for ≥6 months)
  10. HBsAg <4000IU/mL

Participants with well controlled CHB (cohorts 3 and 4):

7. Documented evidence of chronic HBV infection (e.g. HBsAg positive ≥6 months with detectable HBsAg levels at screening) 8. Receipt of only either entecavir or tenofovir for at least 12 months before screening 9. Virally suppressed (HBV DNA <40 IU/mL for ≥6 months) 10. HBsAg <10000 IU/mL

Healthy participants (cohort 5):

11. Considered to be healthy with no current conditions that may significantly impair participant safety or influence study results, in the opinion of the Investigator 12. Adult males or females aged ≥40 to ≤60 years at screening 13. Completed second dose of COVID-19 AZD1222 vaccine 10 to 18 weeks before enrolment

Healthy participants (cohort 6):

14. Considered to be healthy with no current conditions that may significantly impair participant safety or influence study results, in the opinion of the Investigator 15. Adult males or females aged ≥40 to ≤60 years at screening 16. Completed second dose of Pfizer mRNA COVID 19 vaccine 10 to 18 weeks before enrolment

Exclusion Criteria:

  1. Presence of any significant acute or chronic, uncontrolled medical/ psychiatric illness
  2. Hepatitis C virus antibody positive.
  3. Human immunodeficiency virus antibody positive
  4. History or evidence of autoimmune disease or known immunodeficiency of any cause
  5. Prolonged therapy with immunomodulators (e.g. corticosteroids) or biologics (e.g. monoclonal antibodies, interferon) within 3 months of screening
  6. Receipt of immunoglobulin or other blood products within 3 months prior to screening
  7. Receipt of any investigational drug or vaccine within 3 months prior to screening
  8. Cohorts 1-4: Receipt of any adenoviral vaccine within 3 months prior to administration of ChAdOx1-HBV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0

    Cohorts 5 and 6: Receipt of any adenoviral vaccine (other than AZD1222 per inclusion criterion 13) within 3 months prior to administration of ChAdOx1-HBV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0

  9. Receipt of any live vaccines within 30 days prior to screening
  10. Receipt of any inactivated vaccines within 14 days prior to screening
  11. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  12. Any history of anaphylaxis in reaction to vaccination
  13. Malignancy within 5 years prior to screening with the exception of specific cancers that are cured by surgical resection (e.g. except basal cell skin carcinoma of the skin and cervical carcinoma). Participants under evaluation for possible malignancy are not eligible
  14. Current alcohol or substance abuse judged by the Investigator to potentially interfere with participant safety and compliance
  15. Significant cardiac disease or unstable uncontrolled cardiac disease
  16. Any laboratory test at screening which is abnormal and which is deemed by the Investigator to be clinically significant
  17. Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study Additionally, for healthy participants (cohorts 1, 2, 5 and 6)
  18. HBsAg positive Additionally, for participants with well controlled CHB (cohorts 3 and 4)
  19. Co infection with hepatitis delta
  20. Documented cirrhosis or advanced fibrosis indicated by a liver biopsy within 6 months prior to screening.

    In the absence of an appropriate liver biopsy, either 1 of the following:

    • Screening Fibroscan with a result >9 kPa within ≤6 months of screening or
    • Screening FibroTest >0.48 and aspartate aminotransferase (AST) to platelet ratio index of >1 In the event of discordant results between non-invasive methods, the Fibroscan result will take precedence.
  21. Alanine transaminase (ALT) >3 × upper limit of normal, international normalised ratio (INR) >1.5 unless the participant was stable on an anticoagulant regimen affecting INR, albumin <35 g/L, total bilirubin >2 mg/dL, platelet count <100,000/mL
  22. A history of liver decompensation (e.g. ascites, encephalopathy or variceal haemorrhage)
  23. Prior or current hepatocellular carcinoma
  24. Chronic liver disease of a non HBV aetiology
  25. Any herbal supplements and or other medicines with potential liver toxicity within the previous 3 months prior to enrolment into this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04297917


Contacts
Layout table for location contacts
Contact: General Enquiries +44 01865 818808 enquiries@vaccitech.co.uk

Locations
Layout table for location information
United Kingdom
University Hospital Southampton NHS Foundation Trust Not yet recruiting
Southampton, Hampshire, United Kingdom, SO16 6YD
Contact: Mark Wright, PhD    02380777222 ext 4129    Mark.wright@uhs.nhs.uk   
Oxford University Hospitals Nhs Foundation Trust Not yet recruiting
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Contact: Paola Cicconi, MD    + 44 (0) 1865 611413    paola.cicconi@ndm.ox.ac.uk   
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) Suspended
Headington, Oxford, United Kingdom, OX3 7LE
Medicines Evaluations Unit Recruiting
Manchester, United Kingdom, M23 9QZ
Contact: Recruitment Team MEU    0800 655 6553    enquiries@meu.org.uk   
Principal Investigator: Dave Singh, MD, FERS         
Sponsors and Collaborators
Vaccitech (UK) Limited
Layout table for additonal information
Responsible Party: Vaccitech (UK) Limited
ClinicalTrials.gov Identifier: NCT04297917    
Other Study ID Numbers: HBV001
First Posted: March 6, 2020    Key Record Dates
Last Update Posted: August 19, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis
Liver Diseases
Digestive System Diseases
Blood-Borne Infections
Communicable Diseases
Infections
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human